Online inquiry

IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13295MR)

This product GTTS-WQ13295MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PTK7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001270398.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5754
UniProt ID Q13308
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13295MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2950MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ10052MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ6294MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ13800MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ5251MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ6656MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ4818MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ399MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW